Advertisement

Mycopathologia

, Volume 182, Issue 1–2, pp 127–141 | Cite as

New Antifungal Agents and New Formulations Against Dermatophytes

  • Aditya K. GuptaEmail author
  • Kelly A. Foley
  • Sarah G. Versteeg
Article

Abstract

A variety of oral and topical antifungal agents are available for the treatment of superficial fungal infections caused by dermatophytes. This review builds on the antifungal therapy update published in this journal for the first special issue on Dermatophytosis (Gupta and Cooper 2008;166:353–67). Since 2008, there have not been additions to the oral antifungal armamentarium, with terbinafine, itraconazole, and fluconazole still in widespread use, albeit for generally more severe or recalcitrant infections. Griseofulvin is used in the treatment of tinea capitis. Oral ketoconazole has fallen out of favor in many jurisdictions due to risks of hepatotoxicity. Topical antifungals, applied once or twice daily, are the primary treatment for tinea pedis, tinea corporis/tinea cruris, and mild cases of tinea unguium. Newer topical antifungal agents introduced include the azoles, efinaconazole, luliconazole, and sertaconazole, and the oxaborole, tavaborole. Research is focused on developing formulations of existing topical antifungals that utilize novel delivery systems in order to enhance treatment efficacy and compliance.

Keywords

Tinea capitis Tinea corporis Tinea cruris Tinea pedis Onychomycosis Topical antifungals 

References

  1. 1.
    Nweze EI, Eke I. Dermatophytosis in northern Africa. Mycoses. 2016;59:137–44.CrossRefPubMedGoogle Scholar
  2. 2.
    Panthagani AP, Tidman MJ. Diagnosis directs treatment in fungal infections of the skin. The Practitioner. 2015;259(25–9):3.Google Scholar
  3. 3.
    Rosen T. Mycological considerations in the topical treatment of superficial fungal infections. J Drugs Dermatol. 2016;15:49–55.Google Scholar
  4. 4.
    Murmu S, Debnath C, Pramanik AK, et al. Detection and characterization of zoonotic dermatophytes from dogs and cats in and around Kolkata. Vet World. 2015;8:1078–82.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Sahoo AK, Mahajan R. Management of tinea corporis, tinea cruris, and tinea pedis: a comprehensive review. Indian Dermatol Online J. 2016;7:77–86.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Jaradat SW, Cubillos S, Krieg N, et al. Low DEFB4 copy number and high systemic hBD-2 and IL-22 levels are associated with dermatophytosis. J Invest Dermatol. 2015;135:750–8.CrossRefPubMedGoogle Scholar
  7. 7.
    Bickers DR, Lim HW, Margolis D, et al. The burden of skin diseases: 2004 a joint project of the American Academy of Dermatology Association and the Society for investigative dermatology. J Am Acad Dermatol. 2006;55:490–500.CrossRefPubMedGoogle Scholar
  8. 8.
    Ghannoum MA, Hajjeh RA, Scher R, et al. A large-scale North American study of fungal isolates from nails: the frequency of onychomycosis, fungal distribution, and antifungal susceptibility patterns. J Am Acad Dermatol. 2000;43:641–8.CrossRefPubMedGoogle Scholar
  9. 9.
    Panackal A, Halpern E, Watson A. Cutaneous fungal infections in the United States: analysis of the National Ambulatory Medical Care Survey (NAMCS) and National Hospital Ambulatory Medical Care Survey (NHAMCS), 1995–2004. Int J Dermatol. 2009;48:704–12.CrossRefPubMedGoogle Scholar
  10. 10.
    Sais G, Jucglà A, Peyrí J. Prevalence of dermatophyte onychomycosis in Spain: a cross-sectional study. Br J Dermatol. 1995;132:758–61.CrossRefPubMedGoogle Scholar
  11. 11.
    Roberts DT. Prevalence of dermatophyte onychomycosis in the United Kingdom: results of an omnibus survey. Br J Dermatol. 1992;126(Suppl 39):23–7.CrossRefPubMedGoogle Scholar
  12. 12.
    Heikkilä H, Stubb S. The prevalence of onychomycosis in Finland. Br J Dermatol. 1995;133:699–703.CrossRefPubMedGoogle Scholar
  13. 13.
    Havlickova B, Czaika VA, Friedrich M. Epidemiological trends in skin mycoses worldwide. Mycoses. 2008;51(Suppl 4):2–15.CrossRefPubMedGoogle Scholar
  14. 14.
    Food and Drug Administration. FDA Drug Safety Communication: FDA limits usage of Nizoral (ketoconazole) oral tablets due to potentially fatal liver injury and risk of drug interactions and adrenal gland problems [Internet]. 2013. http://www.fda.gov/drugs/drugsafety/ucm362415.htm.
  15. 15.
    Al Hasan M, Fitzgerald SM, Saoudian M, Krishnaswamy G. Dermatology for the practicing allergist: tinea pedis and its complications. Clin Mol Allergy. 2004;2:5.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Ilkit M, Durdu M. Tinea pedis: the etiology and global epidemiology of a common fungal infection. Crit Rev Microbiol. 2014;41:374–88.CrossRefPubMedGoogle Scholar
  17. 17.
    Stein GLF, Vlahovic T, Verma A, Olayinka B, Fleischer AB. Naftifine hydrochloride gel 2%: an effective topical treatment for moccasin-type Tinea pedis. J Drugs Dermatol. 2015;14:1138–44.Google Scholar
  18. 18.
    Caputo R, De Boulle K, Del Rosso J, Nowicki R. Prevalence of superficial fungal infections among sports-active individuals: results from the Achilles survey, a review of the literature. J Eur Acad Dermatol Venereol. 2001;15:312–6.PubMedGoogle Scholar
  19. 19.
    Semel JD, Goldin H. Association of athlete’s foot with cellulitis of the lower extremities: diagnostic value of bacterial cultures of ipsilateral interdigital space samples. Clin Infect Dis. 1996;23:1162–4.CrossRefPubMedGoogle Scholar
  20. 20.
    Gupta AK, Cooper EA. Update in antifungal therapy of dermatophytosis. Mycopathologia. 2008;166:353–67.CrossRefPubMedGoogle Scholar
  21. 21.
    Villars V, Jones TC. Clinical efficacy and tolerability of terbinafine (Lamisil)—a new topical and systemic fungicidal drug for treatment of dermatomycoses. Clin Exp Dermatol. 1989;14:124–7.CrossRefPubMedGoogle Scholar
  22. 22.
    Novartis Pharmaceuticals Canada Inc. Pr LAMISIL* (terbinafine hydrochloride) 250 mg tablets (expressed as base) topical cream 1% w/w (10 mg/g) topical spray solution 1% w/w (10 mg/g) Antifungal Agent [Internet]. 2016. http://webprod5.hc-sc.gc.ca/dpd-bdpp/info.do?code=14532&lang=eng. Accessed 14 April 2016.
  23. 23.
    Tausch I, Decroix J, Gwiezdzinski Z, et al. Short-term itraconazole versus terbinafine in the treatment of tinea pedis or manus. Int J Dermatol. 1998;37:140–2.CrossRefPubMedGoogle Scholar
  24. 24.
    Diflucan (Fluconazole Tablets) (Fluconazole for Oral Suspension) [Internet]. 2014. http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/019949s060,020090s044lbl.pdf. Accessed 22 April 2016.
  25. 25.
    Nozickova M, Koudelkova V, Kulikova Z, et al. A comparison of the efficacy of oral fluconazole, 150 mg/week versus 50 mg/day, in the treatment of tinea corporis, tinea cruris, tinea pedis, and cutaneous candidosis. Int J Dermatol. 1998;37:703–5.CrossRefPubMedGoogle Scholar
  26. 26.
    Terbinafine [Internet]. PubChem2016 [cited 2016 Apr 26]: https://pubchem.ncbi.nlm.nih.gov/compound/1549008.
  27. 27.
    Itraconazole [Internet]. PubChem2016 [cited 2016 Apr 26]: https://pubchem.ncbi.nlm.nih.gov/compound/55283.
  28. 28.
    Fluconazole [Internet]. PubChem2016 [cited 2016 Apr 26]: https://pubchem.ncbi.nlm.nih.gov/compound/3365.
  29. 29.
    Hu Z, Zhang J, Cheng X. Antifungal efficiency of miconazole and econazole and the interaction with transport protein: a comparative study. Pharm Biol. 2015;53:251–61.CrossRefPubMedGoogle Scholar
  30. 30.
    Lamisil AT. Terbinafine hydrochloride cream 1% antifungal. Full prescription strength cream. [Internet]. FDA US Food Drug Adm. 2007 [cited 2016 Apr 26]: http://www.accessdata.fda.gov/drugsatfda_docs/label/2007/020980s005lbl.pdf.
  31. 31.
    Loprox cream (cicloporix) 0.77% [Internet]. [cited 2016 Apr 26]: http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/018748s024,019824s023,020519s016lbl.pdf.
  32. 32.
    Seebacher C, Nietsch KH, Ulbricht HM. A multicenter, open-label study of the efficacy and safety of ciclopirox nail lacquer solution 8% for the treatment of onychomycosis in patients with diabetes. Cutis. 2001;68:17–22.PubMedGoogle Scholar
  33. 33.
    Weir S, Patton L, Castle K, et al. The repositioning of the anti-fungal agent ciclopirox olamine as a novel therapeutic agent for the treatment of haematologic malignancy. J Clin Pharm Ther. 2011;36:128–37.CrossRefPubMedGoogle Scholar
  34. 34.
    Apo-ciclopirox, ciclopirox (topical solution 8% w/w). Product monograph. Health Can Prod Drug Data Base Apotex Inc Aug 28, Inc. 2007. http://webprod5.hc-sc.gc.ca/dpd-bdpp/info.do?code=78435&lang=eng. Accessed 22 April 2016.
  35. 35.
    Gupta AK, Skinner AR, Cooper EA. Evaluation of the efficacy of ciclopirox 0.77% gel in the treatment of tinea pedis interdigitalis (dermatophytosis complex) in a randomized, double-blind, placebo-controlled trial. Int J Dermatol. 2005;44:590–3.CrossRefPubMedGoogle Scholar
  36. 36.
    Valeant INTL. ERTACZO (SERTACONAZOLE NITRATE) CREAM, 2% [Internet]. 2003 [cited 2016 Mar 10]: http://www.accessdata.fda.gov/drugsatfda_docs/label/2003/21385_Ertaczo_lbl.pdf. Accessed 22 April 2016.
  37. 37.
    Croxtall JD, Plosker GL. Sertaconazole: a review of its use in the management of superficial mycoses in dermatology and gynaecology. Drugs. 2009;69:339–59.CrossRefPubMedGoogle Scholar
  38. 38.
    Borelli C, Klövekorn G, Ernst T-M, et al. Comparative study of 2% sertaconazole solution and cream formulations in patients with tinea corporis, tinea pedis interdigitalis, or a corresponding candidosis. Am J Clin Dermatol. 2007;8:371–8.CrossRefPubMedGoogle Scholar
  39. 39.
    Scher RK, Nakamura N, Tavakkol A. Luliconazole: a review of a new antifungal agent for the topical treatment of onychomycosis. Mycoses. 2014;57:389–93.CrossRefPubMedGoogle Scholar
  40. 40.
    Jarratt M, Jones T, Adelglass J, et al. Efficacy and safety of once-daily luliconazole 1% cream in patients ≥12 years of age with interdigital tinea pedis: a phase 3, randomized, double-blind, vehicle-controlled study. J Drugs Dermatol. 2014;13:838–46.PubMedGoogle Scholar
  41. 41.
    Elewski BE, Vlahovic TC. Econazole nitrate foam 1% for the treatment of tinea pedis: results from two double-blind, vehicle-controlled, phase 3 clinical trials. J Drugs Dermatol. 2014;13:803–8.PubMedGoogle Scholar
  42. 42.
    Monk JP, Brogden RN. Naftifine. A review of its antimicrobial activity and therapeutic use in superficial dermatomycoses. Drugs. 1991;42:659–72.CrossRefPubMedGoogle Scholar
  43. 43.
    Evans EG, James IG, Seaman RA, Richardson MD. Does naftifine have anti-inflammatory properties? A double-blind comparative study with 1% clotrimazole/1% hydrocortisone in clinically diagnosed fungal infection of the skin. Br J Dermatol. 1993;129:437–42.CrossRefPubMedGoogle Scholar
  44. 44.
    Rotta I, Ziegelmann PK, Otuki MF, et al. Efficacy of topical antifungals in the treatment of dermatophytosis: a mixed-treatment comparison meta-analysis involving 14 treatments. JAMA Dermatol. 2013;149:341–9.CrossRefPubMedGoogle Scholar
  45. 45.
    Bell-Syer SEM, Khan SM, Torgerson DJ. Oral treatments for fungal infections of the skin of the foot. Cochrane Database Syst Rev. 2012;10:CD003584.PubMedGoogle Scholar
  46. 46.
    Merlin K, Kilkenny M, Plunkett A, Marks R. The prevalence of common skin conditions in Australian school students: 4 Tinea pedis. Br J Dermatol. 1999;140:897–901.CrossRefPubMedGoogle Scholar
  47. 47.
    Hammer TR, Mucha H, Hoefer D. Dermatophyte susceptibility varies towards antimicrobial textiles. Mycoses. 2012;55:344–51.CrossRefPubMedGoogle Scholar
  48. 48.
    Fujiwara Y, Kishida K, Terao M, et al. Beneficial effects of foot care nursing for people with diabetes mellitus: an uncontrolled before and after intervention study. J Adv Nurs. 2011;67:1952–62.CrossRefPubMedGoogle Scholar
  49. 49.
    Gupta AK, Chaudhry M, Elewski B. Tinea corporis, tinea cruris, tinea nigra, and piedra. Dermatol Clin. 2003;21:395–400.CrossRefPubMedGoogle Scholar
  50. 50.
    Moriarty B, Hay R, Morris-Jones R. The diagnosis and management of tinea. BMJ. 2012;345:e4380.CrossRefPubMedGoogle Scholar
  51. 51.
    van Zuuren EJ, Fedorowicz Z, El-Gohary M. Evidence-based topical treatments for tinea cruris and tinea corporis: a summary of a Cochrane systematic review. Br J Dermatol. 2015;172:616–41.CrossRefPubMedGoogle Scholar
  52. 52.
    Alston SJ, Cohen BA, Braun M. Persistent and recurrent tinea corporis in children treated with combination antifungal/corticosteroid agents. Pediatrics. 2003;111:201–3.CrossRefPubMedGoogle Scholar
  53. 53.
    Gupta AK, Cooper EA, Ryder JE, et al. Optimal management of fungal infections of the skin, hair, and nails. Am J Clin Dermatol. 2004;5:225–37.CrossRefPubMedGoogle Scholar
  54. 54.
    Verma SB, Vasani R. Male genital dermatophytosis–clinical features and the effects of the misuse of topical steroids and steroid combinations—an alarming problem in India. Mycoses. 2016. doi: 10.1111/myc.12503.Google Scholar
  55. 55.
    Choudhary S, Bisati S, Singh A, Koley S. Efficacy and safety of terbinafine hydrochloride 1% cream versus sertaconazole nitrate 2% cream in Tinea corporis and Tinea cruris: a comparative therapeutic trial. Indian J Dermatol. 2013;58:457–60.CrossRefPubMedPubMedCentralGoogle Scholar
  56. 56.
    Shivamurthy RPM, Reddy SGH, Kallappa R, et al. Comparison of topical anti- fungal agents sertaconazole and clotrimazole in the treatment of tinea corporis-an observational study. J Clin Diagn Res. 2014;8:HC09–12.PubMedPubMedCentralGoogle Scholar
  57. 57.
    Pande VV, Kadnor NA, Kadam RN, Upadhye SA. Fabrication and characterization of sertaconazole nitrate microsponge as a topical drug delivery system. Indian J Pharm Sci. 2015;77:675–80.CrossRefPubMedPubMedCentralGoogle Scholar
  58. 58.
    Sahoo S, Pani NR, Sahoo SK. Effect of microemulsion in topical sertaconazole hydrogel: in vitro and in vivo study. Drug Deliv. 2016;23:338–45.CrossRefPubMedGoogle Scholar
  59. 59.
    Gupta AK, Daigle D. A critical appraisal of once-daily topical luliconazole for the treatment of superficial fungal infections. Infect Drug Resist. 2016;9:1–6.CrossRefPubMedPubMedCentralGoogle Scholar
  60. 60.
    Jones TM, Jarratt MT, Mendez-Moguel I, et al. A randomized, multicenter, double-blind, vehicle-controlled study evaluating the efficacy and safety of luliconazole cream 1% once daily for 7 days in patients aged ≥12 years with tinea cruris. J Drugs Dermatol. 2014;13:32–8.PubMedGoogle Scholar
  61. 61.
    Jerajani H, Janaki C, Kumar S, Phiske M. Comparative assessment of the efficacy and safety of sertaconazole (2%) cream versus terbinafine cream (1%) versus luliconazole (1%) cream in patients with dermatophytoses: a pilot study. Indian J Dermatol. 2013;58:34–8.CrossRefPubMedPubMedCentralGoogle Scholar
  62. 62.
    Selvan AT, Girisha G, Suthakaran R. Comparative evaluation of newer topical antifungal agents in the treatment of superficial fungal infections (tinea or dermatophytic). Int Res J Pharm. 2013;4:224–8.CrossRefGoogle Scholar
  63. 63.
    Choudhary SV, Aghi T, Bisati S. Efficacy and safety of terbinafine hydrochloride 1% cream versus eberconazole nitrate 1% cream in localised tinea corporis and tinea cruris. Indian Dermatol Online J. 2014;5:128–31.CrossRefPubMedPubMedCentralGoogle Scholar
  64. 64.
    Khosravi AR, Shokri H, Vahedi G. Factors in etiology and predisposition of adult Tinea capitis and review of published literature. Mycopathologia. 2016;181:371–8.CrossRefPubMedGoogle Scholar
  65. 65.
    Fuller LC, Barton RC, Mohd Mustapa MF, et al. British Association of Dermatologists’ guidelines for the management of tinea capitis 2014. Br J Dermatol. 2014;171:454–63.CrossRefPubMedGoogle Scholar
  66. 66.
    Bortolussi R, Martin S, Canadian Paediatric Society, Infectious Diseases and Immunization Committee. Antifungal agents for common outpatient paediatric infections. 2014. http://www.cps.ca/documents/position/antifungal-agents-common-infections. Accessed 22 April 2016.
  67. 67.
    Gonzalez U, Seaton T, Bergus G, Jacobson J, Martinez-Monzon C. Systemic antifungal therapy for tinea capitis in children (Review). Cochrane Database Syst Rev. 2007;CD004685.Google Scholar
  68. 68.
    Mashiah J, Kutz A, Ben Ami R, et al. Tinea capitis outbreak among paediatric refugee population, an evolving healthcare challenge. Mycoses. 2016. doi: 10.1111/myc.12501.PubMedGoogle Scholar
  69. 69.
    Bortolussi R, Martin S. Antifungal agents for common outpatient paediatric infections. Can Paediatr Soc. 2016;1–5. http://www.cps.ca/documents/position/antifungal-agents-common-infections. Accessed 22 April 2016.
  70. 70.
    Suh D-C, Friedlander SF, Raut M, et al. Tinea capitis in the United States: diagnosis, treatment, and costs. J Am Acad Dermatol. 2006;55:1111–2.CrossRefPubMedGoogle Scholar
  71. 71.
    del Boz J, Crespo V, Rivas-Ruiz F, de Troya M. A 30 year survey of paediatric tinea capitis in southern Spain. J Eur Acad Dermatol Venereol. 2011;25:170–4.CrossRefPubMedGoogle Scholar
  72. 72.
    Elewski BE. Tinea capitis: a current perspective. J Am Acad Dermatol. 2000;42:1–20.CrossRefPubMedGoogle Scholar
  73. 73.
    Brilhante RSN, Cordeiro RA, Rocha MFG, et al. Tinea capitis in a dermatology center in the city of Fortaleza, Brazil: the role of Trichophyton tonsurans. Int J Dermatol. 2004;43:575–9.CrossRefPubMedGoogle Scholar
  74. 74.
    Mebazaa A, Oumari KEL, Ghariani N, et al. Tinea capitis in adults in Tunisia. Int J Dermatol. 2010;49:513–6.CrossRefPubMedGoogle Scholar
  75. 75.
    Zur RL, Shapero J, Shapero H. Barriers to treatment of Tinea capitis in children living in the Jane Finch community of Toronto. J Cutan Med Surg. 2015;19:484–7.CrossRefPubMedGoogle Scholar
  76. 76.
    Chen C, Koch LH, Dice JE, et al. A randomized, double-blind study comparing the efficacy of selenium sulfide shampoo 1% and ciclopirox shampoo 1% as adjunctive treatments for tinea capitis in children. Pediatr Dermatol. 2010;27:459–62.CrossRefPubMedGoogle Scholar
  77. 77.
    González U, Seaton T, Bergus G, Jacobson J, Martínez-Monzón C. Systemic antifungal therapy for tinea capitis in children. Cochrane Database Syst Rev. 2007;CD004685.Google Scholar
  78. 78.
    Lamisil. Package Insert: LAMISIL (terbinafine hydrochloride) Tablets, 250 mg Drugs@FDA: FDA Approved Drug Products 2012 [Internet]. http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020539s021lbl.pdf. Accessed 22 April 2016.
  79. 79.
    Annex 1 19th WHO Model List of Essential Medicines [Internet]. 2015 [cited 2016 Apr 25]: http://www.who.int/medicines/publications/essentialmedicines/EML2015_8-May-15.pdf.
  80. 80.
    Grifulvin V. Griseofulvin Tablets, USP (Microsize) and Griseofulvin Oral Suspension, USP (Microsize) [Internet]. 2011. http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/062279s022lbl.pdf. Accessed 22 April 2016.
  81. 81.
    Abdel-Rahman SM, Herron J, Fallon-Friedlander S, et al. Pharmacokinetics of terbinafine in young children treated for tinea capitis. Pediatr Infect Dis J. 2005;24:886–91.CrossRefPubMedGoogle Scholar
  82. 82.
    Seebacher C, Abeck D, Brasch J, et al. Tinea capitis. J Dtsch Dermatol Ges. 2006;4:1085–91.CrossRefPubMedGoogle Scholar
  83. 83.
    Gupta AK, Alexis ME, Raboobee N, et al. Itraconazole pulse therapy is effective in the treatment of tinea capitis in children: an open multicentre study. Br J Dermatol. 1997;137:251–4.CrossRefPubMedGoogle Scholar
  84. 84.
    Pfizer. Diflucan tablets (Fluconazole) Label Information [Internet]. 2011 [cited 2012 May 30] http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/019949s055,019950s059,020090s038lbl.pdf.
  85. 85.
    Shemer A, Plotnik IB, Davidovici B, et al. Treatment of tinea capitis–griseofulvin versus fluconazole—a comparative study. J Dtsch Dermatol Ges. 2013;11(737–41):737–42.PubMedGoogle Scholar
  86. 86.
    Allen HB, Honig PJ, Leyden JJ, McGinley KJ. Selenium sulfide: adjunctive therapy for tinea capitis. Pediatrics. 1982;69:81–3.PubMedGoogle Scholar
  87. 87.
    Greer DL. Treatment of tinea capitis with itraconazole. J Am Acad Dermatol. 1996;35:637–8.CrossRefPubMedGoogle Scholar
  88. 88.
    White JML, Higgins EM, Fuller LC. Screening for asymptomatic carriage of Trichophyton tonsurans in household contacts of patients with tinea capitis: results of 209 patients from South London. J Eur Acad Dermatol Venereol. 2007;21:1061–4.CrossRefPubMedGoogle Scholar
  89. 89.
    Shemer A, Grunwald MH, Gupta AK, et al. Griseofulvin and fluconazole reduce transmission of Tinea capitis in schoolchildren. Pediatr Dermatol. 2015;32:696–700.CrossRefPubMedGoogle Scholar
  90. 90.
    Ghannoum MA, Hajjeh RA, Scher R, et al. A large-scale North American study of fungal isolates from nails: the frequency of onychomycosis, fungal distribution, and antifungal susceptibility patterns. J Am Acad Dermatol. 2000;43:641–8.CrossRefPubMedGoogle Scholar
  91. 91.
    Gupta AK, Daigle D, Foley KA. Topical therapy for toenail onychomycosis: an evidence-based review. Am J Clin Dermatol. 2014;15:489–502.CrossRefPubMedGoogle Scholar
  92. 92.
    Gupta AK, Ryder JE. The use of oral antifungal agents to treat onychomycosis. Dermatol Clin. 2003;21:469–79.CrossRefPubMedGoogle Scholar
  93. 93.
    de Sá DC, Lamas APB, Tosti A. Oral therapy for onychomycosis: an evidence-based review. Am J Clin Dermatol. 2014;15:17–36.PubMedGoogle Scholar
  94. 94.
    Raschi E, Poluzzi E, Koci A, Caraceni P, Ponti FD. Assessing liver injury associated with antimycotics: concise literature review and clues from data mining of the FAERS database. World J Hepatol. 2014;6:601–12.PubMedPubMedCentralGoogle Scholar
  95. 95.
    Zaug M. Amorolfine nail lacquer: clinical experience in onychomycosis. J Eur Acad Dermatol Venereol. 1995;4:S23–30.CrossRefGoogle Scholar
  96. 96.
    Gupta AK, Fleckman P, Baran R. Ciclopirox nail lacquer topical solution 8% in the treatment of toenail onychomycosis. J Am Acad Dermatol. 2000;43:S70–80.CrossRefPubMedGoogle Scholar
  97. 97.
    Elewski BE, Rich P, Pollak R, et al. Efinaconazole 10% solution in the treatment of toenail onychomycosis: two phase III multicenter, randomized, double-blind studies. J Am Acad Dermatol. 2013;68:600–8.CrossRefPubMedGoogle Scholar
  98. 98.
    Elewski BE, Aly R, Baldwin SL, et al. Efficacy and safety of tavaborole topical solution, 5%, a novel boron-based antifungal agent, for the treatment of toenail onychomycosis: results from 2 randomized phase-III studies. J Am Acad Dermatol. 2015;73:62–9.CrossRefPubMedGoogle Scholar
  99. 99.
    Hammer TR, Mucha H, Hoefer D. Infection risk by dermatophytes during storage and after domestic laundry and their temperature-dependent inactivation. Mycopathologia. 2011;171:43–9.CrossRefPubMedGoogle Scholar
  100. 100.
    Gupta AK, Elewski BE, Rosen T, et al. Onychomycosis: strategies to minimize recurrence. J Drugs Dermatol. 2016;15:279–82.PubMedGoogle Scholar
  101. 101.
    Sigurgeirsson B, Olafsson J, Steinsson J, Kerrouche N, Sidou F. Efficacy of amorolfine nail lacquer for the prophylaxis of onychomycosis over 3 years. J Eur Acad Dermatol Venereol. 2010;24:910–5.CrossRefPubMedGoogle Scholar
  102. 102.
    Gupta AK, Daigle D, Foley KA. Network meta-analysis of onychomycosis treatments. Skin Appendage Disord. 2015;1:74–81.CrossRefPubMedPubMedCentralGoogle Scholar
  103. 103.
    Gupta AK, Paquet M, Simpson F, Tavakkol A. Terbinafine in the treatment of dermatophyte toenail onychomycosis: a meta-analysis of efficacy for continuous and intermittent regimens. J Eur Acad Dermatol Venereol. 2013;27:267–72.CrossRefPubMedGoogle Scholar
  104. 104.
    Gupta AK, Drummond-Main C, Cooper EA, et al. Systematic review of nondermatophyte mold onychomycosis: diagnosis, clinical types, epidemiology, and treatment. J Am Acad Dermatol. 2012;66:494–502.CrossRefPubMedGoogle Scholar
  105. 105.
    Sigurgeirsson B, Billstein S, Rantanen T, et al. L.I.ON. Study: efficacy and tolerability of continuous terbinafine (Lamisil) compared to intermittent itraconazole in the treatment of toenail onychomycosis. Lamisil versus itraconazole in onychomycosis. Br J Dermatol. 1999;141(Suppl 56):5–14.CrossRefPubMedGoogle Scholar
  106. 106.
    Iorizzo M, Hartmane I, Derveniece A, Mikazans I. Ciclopirox 8% HPCH nail lacquer in the treatment of mild-to-moderate onychomycosis: a randomized, double-blind amorolfine controlled study using a blinded evaluator. Skin Appendage Disord. 2016;1:134–40.CrossRefPubMedGoogle Scholar
  107. 107.
    Baran R, Tosti A, Hartmane I, et al. An innovative water-soluble biopolymer improves efficacy of ciclopirox nail lacquer in the management of onychomycosis. J Eur Acad Dermatol Venereol. 2009;23:773–81.CrossRefPubMedGoogle Scholar
  108. 108.
    Gupta A, Cernea M. How effective is efinaconazole in the management of onychomycosis? Expert Opin Pharmacother. 2016;17:611–8.CrossRefPubMedGoogle Scholar
  109. 109.
    Gupta AK, Daigle D. Tavaborole (AN-2690) for the treatment of onychomycosis of the toenail in adults. Expert Rev Anti Infect Ther. 2014;12:735–42.CrossRefPubMedGoogle Scholar
  110. 110.
    Gupta AK, Studholme C. Novel investigational therapies for onychomycosis: an update. Expert Opin Investig Drugs. 2016;25:297–305.CrossRefPubMedGoogle Scholar
  111. 111.
    Sakamoto M, Sugimoto N, Kawabata H, et al. Transungual delivery of efinaconazole: its deposition in the nail of onychomycosis patients and in vitro fungicidal activity in human nails. J Drugs Dermatol. 2014;13:1388–92.PubMedGoogle Scholar
  112. 112.
    Alley MR, Baker SJ, Beutner KR, Plattner J. Recent progress on the topical therapy of onychomycosis. Expert Opin Investig Drugs. 2007;16:157–67.CrossRefPubMedGoogle Scholar
  113. 113.
    Olafsson JH. Combination therapy for onychomycosis. Br J Dermatol. 2003;149:15–8.CrossRefPubMedGoogle Scholar
  114. 114.
    Avner S, Nir N, Henri T. Combination of oral terbinafine and topical ciclopirox compared to oral terbinafine for the treatment of onychomycosis. J Dermatol Treat. 2005;16:327–30.CrossRefGoogle Scholar
  115. 115.
    Baran R, Sigurgeirsson B, de Berker D, et al. A multicentre, randomized, controlled study of the efficacy, safety and cost-effectiveness of a combination therapy with amorolfine nail lacquer and oral terbinafine compared with oral terbinafine alone for the treatment of onychomycosis with matrix involvement. Br J Dermatol. 2007;157:149–57.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media Dordrecht 2016

Authors and Affiliations

  • Aditya K. Gupta
    • 1
    • 2
    Email author
  • Kelly A. Foley
    • 2
  • Sarah G. Versteeg
    • 2
  1. 1.Department of MedicineUniversity of TorontoTorontoCanada
  2. 2.Mediprobe Research Inc.LondonCanada

Personalised recommendations